Indeed, the ExoDxTMProstate IntelloScore (EPI) test (Exosome Diagnostics, Inc., Waltham, MA, USA) has been certified by the FDA to discriminate indolent from clinically significant PCa, based on the measurement in urine of three PCa-specific exosome-derived RNA biomarkers (ERG, PCA3, and SPDEF) [82]. The gene discussed is PCA3; the disease is posterior cortical atrophy.